Less Can Be More for Gene Dose and Drug Sensitivity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26199390.
- Also identified by DOI 10.1158/1078-0432.CCR-15-1153.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CDK4 is preclinically validated as a therapeutic target in PAX3-FOXO1 fusion gene-positive rhabdomyosarcomas. Pharmacologic targeting showed sensitivity but, contrary to expectation, CDK4 genomic amplification and overexpression associated with 25% of cases that exhibited the lowest sensitivities. This emphasizes the importance of tumor-specific preclinical studies to define and understand drug sensitivity.
Medical subject headings
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinase 6
- Drug Resistance, Neoplasm
- Gene Amplification
- Oncogene Proteins, Fusion
- Protein Kinase Inhibitors
- Rhabdomyosarcoma